Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2020-04-28 Annual Report
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Annual Report 2019
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2019' and contains comprehensive sections typical of an annual report, including business highlights, CEO statement, consolidated financial statements (income statement, balance sheet, cash flows), accounting policies, and an auditor's report. It covers the full fiscal year 2019 and provides detailed financial data, fitting the definition of a 10-K (Annual Report). FY 2019
2020-04-28 English
Calliditas utser ny Chief Medical Officer
Board/Management Information Classification · 98% confidence The document announces the appointment of a new Chief Medical Officer (CMO), Dr. Richard Philipson, detailing his extensive background, previous roles, and start date. This content directly relates to changes in the company's senior management team. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a formal announcement regarding executive personnel change, making MANG the most appropriate classification.
2020-04-06 Swedish
Calliditas appoints new Chief Medical Officer
Board/Management Information Classification · 100% confidence The document is a press release dated April 6, 2020, announcing the appointment of Dr. Richard Philipson as the new Chief Medical Officer (CMO) and detailing his extensive background in the pharmaceutical industry, particularly in rare diseases. This announcement concerns a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' This perfectly matches the content of the document.
2020-04-06 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document details a change in shareholding percentage for Handelsbanken Fonder AB in Calliditas Therapeutics AB, specifically noting the 'Before the transaction' and 'After the transaction' share counts and the resulting percentage (5.44%). This structure, focusing on changes in significant ownership thresholds (5% limit mentioned), directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2020-04-02 English
Calliditas moves its Annual General Meeting 2020 to June 25
AGM Information Classification · 98% confidence The document explicitly announces a change in the date for the 'Annual General Meeting 2020' (AGM) due to the Covid-19 pandemic. This directly relates to the scheduling and materials surrounding the AGM. Although it mentions the expected publication date of the Annual Report, the primary subject and action of this short announcement is the rescheduling of the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length is very short (1772 chars), suggesting it is an announcement rather than the full meeting materials.
2020-03-30 English
Calliditas flyttar sin Årsstämma 2020 till 25 juni
AGM Information Classification · 95% confidence The document is a short announcement in Swedish regarding Calliditas Therapeutics AB. Key phrases are: 'Calliditas flyttar sin Årsstämma 2020 till 25 juni' (Calliditas moves its Annual General Meeting 2020 to June 25th) and 'Årsredovisningen för 2019 förväntas publiceras den 28 april 2020' (The Annual Report for 2019 is expected to be published on April 28, 2020). Since the document is short (1641 chars) and primarily announces the rescheduling of the AGM and the future publication date of the Annual Report, it is not the AGM material itself (AGM-R) or the Annual Report (10-K). It is an announcement about corporate events and reporting schedules. This fits best under Report Publication Announcement (RPA) as it announces the publication of the Annual Report, or potentially Regulatory Filing (RNS) as a general announcement. Given the specific mention of the upcoming publication of the Annual Report, RPA is a strong candidate, but since it also announces the rescheduling of the AGM, it is a general corporate update. However, the most specific action announced regarding a report is the publication date of the Annual Report. If the document were solely about the AGM date change, AGM-R might apply, but the mention of the Annual Report publication date leans towards RPA or RNS. Since it is an announcement about the timing of a report release, RPA is the most precise fit among the options that aren't the report itself. If it were just the AGM date change without the report mention, AGM-R might be considered, but the structure suggests a general update/announcement.
2020-03-30 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.